

Evaluation of Patients with PNH Treated By Eculizumab: Real World Data from Turkey

Fatma Keklik Karadag, MD,^{*1,2} Mustafa Nuri Yenerel, MD,^{*3,2} Y#lmaz Mehmet, MD,^{*4,2}
Hava uskudar Teke, MD,^{*5,2} Vildan Ozkocaman, MD,^{*6,2} Tulin Tuglular, MD,^{*2,7}
Fuat Erdem, MD,^{*8,2} Ali Unal, MD,^{9,2} Orhan Ayyildiz, MD,^{*2,10} Gulsum Ozet, MD,^{*11,2}
Melda Ozkan, MD,^{*12,2} Emin Kaya, MD,^{*13,2} Mesut Ayer, MD,^{*14,2} Ozan Salim, MD,^{*15,2}
Birol Güvenç, MD,^{*16,2} Hakan Ozdogu, MD,^{*17,2} Özgür Mehtap, MD,^{*18,2} Mehmet Sönmez, MD,^{*19,2}
Nil Güler, MD,^{*20,2} Sibel Kabukcu Hacıoglu, MD,^{*21,2} Ismet Aydogdu, MD,^{*22,2}
Ozlen Bektas, MD,^{*23,2} Selami Kocak Toprak, MD,^{*24,2} Lale Kaynar, MD,^{*25,2} Munci Yagci, MD,^{*25}
Salih Aksu, MDPF.,^{*26,2} Anil Tombak, MD,^{*27,2} Volkan Karakus, MD,^{*28,2} Irfan Yavasoglu, MD,^{*29,2}
Birgül Öneç, MD,^{*30,2} Mehmet Ali Özcan, MD,^{*31,2} Levent Ündar, MD,^{*15,2} R#dvan Ali, MD,^{*32,2}
Celalettin Ustun, MD,³³ Osman Ilhan, MD,^{*34,2} Guray Saydam, MD,^{*1,2} Fahri Sahin, MD^{*35,2}

¹Department of Hematology, Ege University, Izmir, Turkey

²PNH Education and Study Group, Izmir, Turkey

³Istanbul University, Istanbul Faculty of Medicine, Dept.of Internal Medicine div. Of Hematology, Istanbul, Turkey

⁴Department of Hematology, Gaziantep University, Gaziantep, Turkey

⁵Department of Hematology, Eskisehir Osmangazi University, Eskisehir, Turkey

⁶Department of Hematology, Uludag University, Faculty of Medicine, Bursa, Turkey

⁷Department of Hematology, Marmara University, Istanbul, Turkey

⁸Department of Hematology, Atatürk University, Erzurum, Turkey

⁹Department of Hematology, Erciyes University, Kayseri, Turkey

¹⁰Department of hematology, Dicle University, Diyarbakir, Turkey

¹¹Ankara Numune Hospital, Ankara, Turkey

¹²Department of Hematology, Gülhane Research and Training Hospital, Ankara, Turkey

¹³Department of Hematology, Malatya Inonu University, Malatya, Turkey

¹⁴Department of Hematology, Haseki Research and Training Hospital, Istanbul, Turkey

¹⁵Department of Hematology, Akdeniz University, Antalya, Turkey

¹⁶Department of Hematology, Çukurova University, Adana, Turkey

¹⁷Hematology, Baskent University, Adana, Turkey

¹⁸Department of Hematology, Kocaeli University, Kocaeli, Turkey

¹⁹Department of Hematology, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey

²⁰Department of Hematology, Pamukkale University, Denizli, Turkey

²¹Department of Hematology, Pamukkale University, Faculty of Medicine, Denizli, Turkey

²²Department of Hematology, Celal Bayar University, Faculty of Medicine, Manisa, Turkey

²³Department of Hematology, Karadeniz Technical University, Faculty of Medicine, Trabzon, TUR

²⁴Department of Hematology, Ankara University School of Medicine, Ankara, Turkey

²⁵Department of Hematology, Gazi University, Ankara, Turkey

²⁶Department of Hematology, Hacettepe University, Ankara, Turkey

²⁷Department of Hematology, Mersin University, Faculty of Medicine, Mersin, Turkey

²⁸Department of Hematology, Mugla Sitki Kocman University, Faculty of Medicine, Mugla, Turkey

²⁹Department of Hematology, Adnan Menderes University, Aydin, Turkey

³⁰Department of Hematology, Düzce University, Düzce, Turkey

³¹Department of Hematology, Dokuz Eylül University, Izmir, Turkey

³²Department of Hematology, Uludag University, Bursa, Turkey

³³Blood and Marrow Transplant Program, Rush Medical Center, Chicago, IL

³⁴Department of Hematology, Ankara University, Ankara, Turkey

³⁵Department of Hematology, Ege University, Izmir, Turkey

bloodjournal Blood blood (2019) 134 (Supplement_1) : 4805.

<http://doi.org/10.1182/blood-2019-128743>

Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease which is characterized with complement mediated intravascular hemolysis, bone marrow failure and thrombosis. The prevalence of PNH is estimated 1 to 16 cases per million in USA. X-linked somatic mutation of phosphatidylinositol glycan#A (*PIGA*) gene in hematopoietic stem cells causes an impairment of glycosylphosphatidylinositol (GPI) anchored proteins. The absence of GPI#dependent molecules that are CD55 (decay accelerating factor; DAF) and CD59 (membrane inhibitor of reactive lysis; MIRL), normally protect the cell from complement#mediated hemolysis by preventing the formation of the membrane attack complex. The diagnosis is based on flow cytometry which can detect the deficiency of these two complement regulatory proteins. We report a retrospective analysis of demographic and clinical characteristics of PNH patients from different centers.

Material and methods: We conducted a retrospective analysis of the patients' recorded data. Patients' demographics, medical and treatment history, comorbid conditions, PNH clone size, disease characteristics and outcomes, symptoms, PNH-specific treatments, PNH-related events, morbidity (including myeloproliferative disease, other malignancies, and infections), mortality. Clinical data captured include lactate dehydrogenase (LDH) levels, PNH clone size, hemoglobin levels, thrombotic events,

renal functional tests at the time of diagnosis, and other laboratory data. Specific information collected for eculizumab-treated patients includes dosage and dose adjustments and blood cell counts, reticulocyte count and LDH level after eculizumab treatment.

Results: 138 patients were included from 28 different centers. All patients were diagnosed by flow cytometry for GPI-linked antigens on red cells and neutrophils. The number of male (69/138) and female (69/138) patient was equal and the median age was 41 years. Median hemoglobin (hb) level was 8.75 ± 2.13 gr/dL; Platelet (plt) level was 131×10^9 /L at the time of diagnosis. Overall, 49(35,5%) of the patients had been diagnosed with bone marrow failure, including aplastic anemia or hypoplastic anemia (n=31; 22,5%), myelodysplastic syndromes (n=18; 13%). A history of any prior thrombotic event was reported in 45 patients (32,6%). At the time of analysis, 12 (8,7%) patients had pulmonary hypertension. The median granulocyte and monocyte clone size was 63,6% (± 32.26) and 66.76 ± 28.75 respectively. Fatigue (58%) is the most commonly reported symptom and abdominal pain was seen in 8% of patients. After the eculizumab therapy, the median time for normalization of Hb and LDH level were 7 and 14,6 months, respectively. There was no correlation between thrombosis and clone size, hb, plt, LDH level at the time of diagnosis. LDH level was higher in fatigue patients compared with the patients who were not fatigue (p=0.021).

Discussion: PNH is a clonal but non malignant disease that is very rare and knowledge on large case series is really limited. The clinical findings and symptoms could be variable and unfortunately it takes very long time to diagnose because of unawareness of physicians. Eculizumab is a good option in treatment of PNH for improving symptoms of intravascular hemolysis but we still need better understanding of thrombosis mechanism of PNH to better management. In the future, novel inhibitors of the alternative pathway of complement will be used to improve survival and quality of life for PNH patients.

Disclosures

No relevant conflicts of interest to declare.

Author notes

*Asterisk with author names denotes non-ASH members.